US Peptide Science Research Team
November 2, 2026
Between July 1 and October 1, 2026, eight compounding firms initiated recalls affecting 29 peptide products, according to peptidesciencedesk.com. The most significant recalls involved compounded tirzepatide and semaglutide products from facilities including:
According to peptidesciencedesk.com, recalls were classified as Class II, meaning use of or exposure to the recalled product could cause temporary or medically reversible adverse health effects. The data documented that all four Class I recalls during this period involved glutathione products, not GLP-1 compounds.
The primary regulatory concerns fell into three categories:
1. Sterility Assurance Failures
The most common recall reason cited by the FDA was "lack of assurance of sterility." healthcontentworks.com documented that compounded GLP-1 medications dispensed in multi-dose vials present heightened contamination risk. FDA guidance indicates that multi-dose sterile medication vials carry increased bacterial and fungal contamination risk beyond 28 days of first use.
Source research
U.S. Food and Drug Administration (FDA)2. Adverse Event Reports and Manufacturing Defects
As of May 31, 2026, the FDA received 990 adverse event reports associated with compounded semaglutide and more than 730 reports for compounded tirzepatide, according to ushealthdigest.com. Multiple reports cited adverse events including nausea, vomiting, diarrhea, abdominal pain, and constipation, with some cases requiring hospitalization. The agency also documented adverse events related to dosing variability in compounded products.
3. Manufacturing Process Control Issues
Carolina Infusion's recall cited specific process failures: "lack of assurance of sterility related to formulation using bacteriostatic water and related to processing equipment used in compounded product," according to medshadow.org. Apollo Care's recall identified "presence of particulate matter identified as nylon/polyamide and silk/proteinaceous-type material," indicating contamination during manufacturing.
These compounds were not subject to recalls in the 2026 period because they are prohibited from compounding entirely. FDA guidance explicitly states that retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been established as safe and effective for any condition. This prohibition reflects the absence of clinical validation for these compounds and the lack of any FDA-approved reference product for compounding purposes.
Compounded medications operate under a different regulatory framework than FDA-approved pharmaceuticals. According to ushealthdigest.com, compounded drugs do not undergo FDA pre-market review for safety, effectiveness, or quality before marketing. This distinction applies to 503A pharmacies (state-regulated) and 503B outsourcing facilities (subject to limited FDA oversight). Compounding is permitted only when a patient's medical needs cannot be met by an FDA-approved drug or when the approved drug is unavailable.
Tracking is incomplete. Federal law does not require state-licensed 503A pharmacies to submit adverse event reports to the FDA, meaning compounded product adverse events are likely underreported. ushealthdigest.com notes that a report count is a signal, not a rate, and cannot show that a product caused an event. The 990 semaglutide and 730+ tirzepatide adverse event reports represent only reported cases, not the full population of adverse outcomes.
Injectable GLP-1 drugs require refrigeration as specified in their package inserts. healthcontentworks.com documents that improper storage during shipping may compromise drug quality. Temperature excursions can degrade the active pharmaceutical ingredient and potentially generate degradation products of unknown safety.
Once a multi-dose vial is first punctured, the risk of microbial contamination increases substantially over time. FDA guidance recommends that multi-dose vials be discarded within 28 days of first use, even if medication remains. This guidance reflects standard pharmaceutical microbiology practices for injectable solutions, though this interval may vary by product formulation and sterilization method.
peptidesciencedesk.com maintains a searchable recall tracker organized by pharmacy, lot number, and beyond-use date. Researchers should:
The tracker was last updated October 27, 2026, based on FDA records through October 26, 2026.
According to ushealthdigest.com, the FDA assigns recalls to one of three classes:
The 2026 GLP-1 recalls were predominantly Class II, reflecting concerns about sterility and manufacturing defects but not immediate life-threatening risk. However, Class II recalls can escalate if additional safety data emerges.
FDA-approved semaglutide and tirzepatide products undergo rigorous pre-market testing for identity, purity, potency, and sterility. Compounded versions bypass this review. ushealthdigest.com notes that the FDA has identified multiple areas of concern: inconsistent dosing, inadequate sterility assurance, improper storage, and use of compounds (retatrutide, cagrilintide) that lack any FDA-approved reference. The absence of pre-market quality control and post-market surveillance creates an inherent safety gap.
The 2026 compounded GLP-1 recall period represents a significant regulatory intervention addressing systemic quality and safety gaps. The documented adverse event reports—particularly those involving contamination and manufacturing defects—highlight the risks of compounded formulations that lack FDA oversight. Researchers should prioritize verification of product sourcing through official FDA records, maintain awareness of ongoing FDA communications regarding compounding safety concerns, and note that the prohibition on retatrutide and cagrilintide in compounding reflects the regulatory principle that compounds without established safety and efficacy data should not enter the compounding supply chain.